SBIR Phase I: COVID-19 Detection on a Handheld Smartphone-Enabled Platform

SBIR 第一阶段：在支持智能手机的手持平台上检测 COVID-19

• 批准号: 2028308
• 负责人: Katherine Clayton
• 金额: $ 25.6万
• 依托单位: Omnivis LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-01 至 2021-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2028308&HistoricalAwards=false
• 关键词: SBIR; Phase; COVID; 19; Detection

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project is a handheld smartphone-enabled hardware platform for the rapid detection of COVID-19 in nasal swab samples. The proposed project will translate a portable smartphone enabled platform to detect COVID-19 in patient samples in 30-90 minutes in a standard clinical setting or in an even lower-resource facility. After diagnosis, data are immediately recorded and encrypted with geo-mapped and time-stamped for public health use. This novel and proactive approach for detection can enable communities to rapidly detect COVID-19 and monitor outbreak data to suppress disease spread. This Small Business Innovation Research (SBIR) Phase I project addresses the need to develop a rapid and portable COVID-19 point-of-care diagnostic. The scope of the Phase I project is to develop a robust nucleic acid assay to specifically and sensitively detect for COVID-19 in a handheld smartphone-enabled device. This project proposes an optimized nucleic acid amplification assay that is highly selective and rapid, while maintaining sensitivity, specificity, and a low false positive rate. Additionally, the project will test the optimized assay in the presence of nasopharyngeal (nasal) swabs and viral transport media, preparing a robust platform for clinical analysis of both fresh and stored samples. The project will integrate the assay into a sample-to-answer device for fast COVID-19 nucleic acid diagnosis.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）项目的更广泛的影响/商业潜力是一个具有手持智能手机的硬件平台，用于快速检测鼻拭子样品中的Covid-19。拟议的项目将在标准的临床环境中或在较低的资源设施中，在30-90分钟内在30-90分钟内转换一个便携式智能手机平台，以检测患者样品中的COVID-19。诊断后，立即记录和加密数据，并使用地理图和时间戳记，以供公共卫生使用。这种新颖和主动的检测方法可以使社区能够快速检测Covid-19并监测爆发数据以抑制疾病的扩散。这项小型企业创新研究（SBIR）I阶段项目解决了开发快速且便携式Covid-19-19的诊断的必要性。第一阶段项目的范围是开发一种强大的核酸测定法，以在支持手持智能手机的设备中专门和灵敏地检测Covid-19。该项目提出了一种优化的核酸扩增测定法，该测定法具有高度选择性和快速的，同时保持灵敏度，特异性和较低的假阳性速率。此外，该项目将在存在鼻咽（鼻）拭子和病毒传输介质的情况下测试优化的测定法，为新鲜和储存样品的临床分析准备了强大的平台。该项目将将该测定法整合到快速共核-19核酸诊断的样本到答案设备中。该奖项反映了NSF的法定任务，并使用基金会的知识分子优点和更广泛的影响审查标准，被认为值得通过评估来提供支持。